GC Cell and Checkpoint Therapeutics Announce Collaboration to Explore Synergistic Cancer Therapies

Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell thera...

July 16, 2024 | Tuesday | News
Taiwan's Senhwa Biosciences Submits IND to US FDA for Phase I/II Study of Silmitasertib in Pediatric Cancer Treatment

  Senhwa Biosciences, Inc. (TPEx: 6492), announced IND Submission to US FDA for the Phase I/II study of Silmitasertib (CX-4945) in combination with c...

July 12, 2024 | Friday | News
Sciwind Biosciences and HK inno.N Partner to Advance Ecnoglutide for Diabetes and Obesity in South Korea

Sciwind Biosciences Co., Ltd., a clinical stage biopharmaceutical company focused on developing treatments for metabolic disease, and HK inno.N Corporation...

May 07, 2024 | Tuesday | News
Astellas Pharma and Poseida Therapeutics Forge Research Collaboration to Develop Novel CAR-T Cell Therapies for Solid Tumors

Astellas Pharma  and Poseida Therapeutics, Inc.   announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos")...

May 02, 2024 | Thursday | News
QIAGEN Introduces NeuMoDx HIV-1 Quant Assay in Thailand for Blood-Borne Virus Testing

QIAGEN has announced the approval of its NeuMoDx human immunodeficiency virus type 1 (HIV-1) assay for use in Thailand. This approval completes the suite o...

April 15, 2024 | Monday | News
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Incyte and China Medical System Holdings Limited  are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology m...

April 02, 2024 | Tuesday | News
Biocytogen Partners with ABL Bio to Forge Ahead in Bispecific Antibody-Active Ingredient Conjugate Development

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company focused on the development of novel antibody the...

March 26, 2024 | Tuesday | News
Novartis Expands Biopharmaceutical Manufacturing Site in Singapore

The expanded facility will focus on manufacturing therapeutic antibody drugs, contributing to the delivery of breakthrough treatments to patients globally....

March 18, 2024 | Monday | News
Registration Now Open for BIO Asia–Taiwan 2024: A Keystone Event for Asia's Biotech Industry

  The highly anticipated BIO Asia–Taiwan 2024 has officially opened its registration for attendees. Scheduled to take place from July 24 to 28 ...

February 26, 2024 | Monday | News
QIAGEN's QIAstat-Dx Meningitis/Encephalitis Panel Secures HSA Approval, Advancing Syndromic Testing in Singapore

  Meningitis, characterized by inflammation of the protective membranes enveloping the brain and spinal cord, poses a grave medical emergency due to ...

February 07, 2024 | Wednesday | News
HUTCHMED Granted ELUNATE® Approval in Hong Kong for Metastatic Colorectal Cancer Treatment

— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong&...

January 30, 2024 | Tuesday | News
Travere Licenses Sparsentan to Renalys Pharma for Japan, South Korea, Taiwan, and Southeast Asia

Travere Therapeutics, Inc. announced that it has entered into an exclusive licensing agreement with Renalys Pharma, Inc., to bring sparsentan, a dual endot...

January 26, 2024 | Friday | News
ClinChoice Expands Global Presence with Acquisition of CSI in Southeast Asia

ClinChoice further broadens its global footprint and full-service capabilities in more than 30 countries throughout Asia, Europe and North America around t...

January 15, 2024 | Monday | News
China's RemeGen's RC88 earns FDA Fast Track, heralding new hope for ovarian cancer patients

RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, announced recently that its independently dev...

January 15, 2024 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in